The TauRx group of life science companies is focused on the development of novel treatments and diagnostics for Alzheimer's Disease (AD) and other neurodegenerative diseases.
Our team includes highly skilled and internationally recognized pharmaceutical experts in many aspects of drug development. From initial discovery through to clinical trials, data analysis and product registration, we are working together towards halting the progression of Alzheimer's, frontotemporal dementia (FTD) and other neurodegenerative diseases.
Our Protein Aggregation Inhibitors target the underlying pathology of dementia, with the aim of modifying or halting disease progression and an ultimate goal of prevention. Our lead compound, LMTX™, targets aggregation of tau, synuclein, TDP-43 and huntingtin protein. Its primary development in Alzheimer's is focused in its activity as a Tau Aggregation Inhibitor (TAI).
TauRx is incorporated in Singapore with primary research and operations in Aberdeen, Scotland.
September 2014:TauRx Therapeutics…
August 2014:TauRx: In the News
July 2014:TauRx Therapeutics…
April 2014:FTD Global Study…
March 2014:TauRx Chairman to…
FTD Global Study Locator
Alzheimer's Global Study Locator
Genting Invests with TauRx for Stake in Alzheimer's Market Leadership
The Tau-hypothesis of Alzheimer’s disease pathogenesis proposes that age-related malfunctions in the cellular processing of Tau protein, which is a normal component of healthy cells, leads to Tau protein misfolding and loss of neuronal function, then to the formation of neurotoxic aggregates and ultimately disease symptoms. See Science for more.
We are currently conducting Phase 3 clinical trials in both Alzheimer's Disease and Frontotemporal Dementia (FTD). If you are a patient, caregiver, or family member of someone diagnosed with either of these 2 diseases, CLICK HERE to take a short survey and register for notifications when future updates and information are available. If you'd like to learn more please see our Patients & Caregivers section.
Alzheimer’s Innovation: In Our Hands
By 2050, nearly 104 million people [one third of the current U.S. population] are predicted to have Alzheimer’s disease, according to the World Health Organisation. This underscores the need for new treatments to halt and prevent the formation of Tau tangles - the hallmark sign of dementia. See FTD Rationale